Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trialLancet 2021 Oct 18;[EPub Ahead of Print], S Del Prato, SE Kahn, I Pavo, GJ Weerakkody, Z Yang, J Doupis, D Aizenberg, AG Wynne, JS Riesmeyer, RJ Heine, RJ Wiese
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.